Category: Science


Using Zebrafish to Shed New Light on Melanoma

By Cody R. Barnett, MRA Director of Communications | 29 August 2018 In Science

Dr. Liz Patton, a MRA-funded cancer researcher at the Medical Research Council Human Genetics Unit at the University of Edinburgh, is fascinated by learning how things work. Patton has focused her research on better understanding how melanocytes – the cells in our skin that provide us our coloring – develop, divide, migrate, and in some unfortunate circumstances, proliferate uncontrollably turning into melanoma. Her work is providing critical insight into the origin of melanoma and what spurs melanoma to spread throughout the body.

Read More


Maintaining the Pace of Melanoma Innovation in the Era of an Evolving Standard of Care

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 10 August 2018 In Science, Treatment

There is no doubt that treatments for metastatic melanoma have changed dramatically in the decade since MRA’s founding in 2007. How do we keep up the momentum?

Read More


Uveal ‘Clusters’ in Auburn, AL and Huntersville, NC

By Cody R. Barnett, MRA Director of Communications | 18 July 2018 In Allies & Partnerships, Melanoma Stories, News, Science, Treatment

When we talk about melanoma, it’s easy to forget that cutaneous – the most common variety that forms on the skin – isn’t the only game in town. Uveal represents about 5% of all melanomas diagnosed each year. So, when dozens of people from two towns in North Carolina and Alabama were diagnosed with the rare cancer alarm bells sounded.

Read More


Applying AI to Melanoma Detection

5 July 2018 In Prevention, Science

Is AI the future of detecting melanoma early, when it is easiest to cure?

Read More


Making the Most Out of Immunotherapy

11 June 2018 In Science, Treatment

Learn what MRA-funded investigators are doing to optimize immunotherapy for patients.

Read More


We’ve Teamed Up with the American Cancer Society

By Cody R. Barnett, MRA Director of Communications | 7 June 2018 In Allies & Partnerships, Science, Treatment

American Cancer Society and Melanoma Research Alliance have united to fund lifesaving research aimed at reducing side effects and improving outcomes for patients treated with immunotherapy.

Read More


American Cancer Society and Melanoma Research Alliance Fund Five Innovative Approaches to Reduce Immunotherapy Side Effects

10 May 2018 In Allies & Partnerships, Science

As the world marks Melanoma Awareness Month, the American Cancer Society (ACS) and the Melanoma Research Alliance (MRA) selected the first group of scientists to receive newly established research grants to investigate how to reduce rare, but serious, side effects resulting from cancer treatments with checkpoint inhibitors, a type of immunotherapy.

Read More


Tackling Brain Metastases

30 April 2018 In Science, Treatment

Brain metastases (mets) are a frequent and often deadly problem in patients with advanced melanoma. Nearly 40% of patients with metastatic melanoma have brain mets at diagnosis, with an average survival of only 4 months, suggesting a crucial need for treatments that can rid the brain of these tumors1,2. But new cancer treatments are rarely tested in patients with active brain mets. This is largely due to concerns about whether these patients will have side effects unique to brain mets, and poorer outcomes that may negatively weigh against otherwise positive clinical benefits. Another potential concern is whether the drugs will even penetrate the brain, which has a fortress-like ability to keep substances from entering it.

Read More


Are Personalized Vaccines Part of a New Combination Approach to Treating Melanoma?

By Cody R. Barnett, MRA Director of Communications | 29 April 2018 In Allies & Partnerships, Science

Bracing for cold weather and the threat of runny noses and sore throats, millions of Americans are vaccinated for the flu each year. By priming the immune system, the vaccine reduces the risk of catching the flu and, if not successful at preventing it altogether, reduces both the severity and the duration of symptoms. These are ‘one-size-fits-all’ vaccines that are useful for all people. But what if each and every person’s flu, like each person’s melanoma, was unique? You’d need a personalized vaccine that was made and customized for each individual. Dr. Patrick Ott, Clinical Director of the Melanoma Center at the Dana-Farber Cancer Institute and lead researcher on the BJ's Wholesale Club-MRA Team Science Award, is conducting pioneering research to harness the power of personalized vaccines to combat melanoma.

Read More


Melanoma: What You Need to Know

By Cody R. Barnett, MRA Director of Communications | 29 April 2018 In Science

Melanoma is the deadliest form of skin cancer. Rates of melanoma are rising rapidly, especially in younger people. In fact, cases of melanoma have tripled in the last 30 years, at a time when cancer rates for other common cancers have declined.

Do you know the answer to these top ten questions people ask about melanoma?

Read More


Login

×